Responsible regulatory decisions regarding the fate of new chemicals require careful evaluation of a host of health, economic, and social factors, in addition to a thorough evaluation of potential risks. In risk assessment, laboratory animals are used as human surrogates in testing for potential chemical effects since mammals are anatomically, physiologically, and biochemically similar and, in most cases, have similar responses to exogenous chemical, biologic, and physical agents (with differences in response usually quantitative rather than qualitative). Unfortunately for the sake of proper extrapolation to humans, qualitative differences do occur, resulting in species, sex, and/or tissue -specificity in toxicologic/proliferative responses. Since the toxicologic pathologist is trained in comparative medicine he/she must play a primary role in recognizing and demonstrating specificities in tissue alteration of laboratory animals by new chemicals of potential importance to society. A model exemplifying the recognition and demonstration of species, sex, and tissue specificity of test substance response will be described. In this model a presumably unique alteration of male rat kidney occurred in response to a specific class of test substances. The decision tree in establishing specificity, as well as the nature of the test substances, will be described.
INTRODUCTION
I would first like to comment that the over-a11 trend in life expectancy and quality of life has steadily increased with the introduction of new chemicals into the market place, attesting to adequacy of industry and regulatory decision making of the past. Although epidemiologists report increasing incidences of cancer with time, in an apparent conflict with this statement, Dr. John Higginson, internationally reknown epidemiologist of UAREP (University Affiliated for Research in Experimental Pathology), states that the increases recognized in cancer rates are associated with personal habits (e.& tobacco and sunlight). In the past two decades, as longev-I'rcscntcd at tlic Third Intcrnatioiial Symposium of the Society of Toxicologic Pathologists. hlay 13-15, 1984, Arlington. \ ?I\ . ity and quality of life have improved, I further note that our ability to identify potential risk through animal testing and chemical analysis has improved dramatically. Similar improvement in public policy and regulatory decision making is presumably occurring and must occur to avoid stagnation in introduction of new products on which depend, in part, future improvements in health and quality of life. Responsible regulatory decisions regarding the fate of new chemicals require careful evaluation of a host of health, economic, and social factors, in addition to a thorough evaluation of potential risks.
This meeting is creating an interesting blend of scientists from the private sector, regulatory scientists, as well as policy makers. The private sector scientists, specifically the toxicologist pathologist (and with the pathologist forming the cornerstone of this Society), shouId pIay a n integral port in debates ALDEN TOXICOLOGIC PATHOLOGY and decision making regarding risk assessment which I would like to discuss further. I think we, as pathologists and toxicologists, should attempt to keep the science of risk assessment distinct and separate from debates on public policy. In risk assessment, laboratory animals are used as human surrogates in testing for potential chemical effects since mammals are anatomically, physiologically, and biochemically similar and, in most cases, have similar responses to exogenous chemical, biologic, and physical agents (with differences in response usuaIIy quantitative rather than qualitative). There are, of course, other scientific means of risk assessment, including epidemiology and in vitro methodologies. Unfortunately for the sake of proper extrapolation to humans, qualitative differences do occur (in laboratory animal testing) resulting in species, sex, and/or tissue specificity in toxicologic/oncologic responses. However, unless evidence exists to the contrary, a regulator has no choice but to accept that the animal data may be predictive of human response. Decision making in risk assessment as to the absence of predictiveness of a laboratory animal response to a test substance must have a factual basis. Thus, demonstration of a unique response must be based on specific knowledge as to the anatomic, physiologic, and biochemical difference in the laboratory animal compared to humans upon which the unique response is predicated. Since the toxicologic pathologist is trained in comparative medicine (especially including comparative anatomy and physiology), he/she must play a primary role in recognizing and demonstrating specificities in tissue alteration of laboratory animals by new chemicals of potential importance to society.
I would like to describe a model exemplifying the recognition and demonstration of species, sex, and tissue specificity of test substance response. In this model the presumably unique alteration of male rat kidney occurred in response to a specific class of test substances.
UNIQUE MALE RAT KIDNEY TOxlCOLOGIC AND ONCOLOGIC RESPONSE TO VOLATILE HYDROCARBON s
In considering this example I note that there is a growing list of chemicals, predominately volatile hydrocarbons, that are reported to induce morphologic alterations in the male rat kidney. As you can see in Table  I , none of these chemicals appear to affect female rats or several other species of either sex in safety testing.
Without additional information as to the nature of the volatile hydrocarbon effect, one cannot predict whether man is more like the male rat or more like the other species that are demonstrated to be nonresponsive to those compounds. Hence, Procter & Gamble scientists instigated and completed a research effort designed to establish the pathogenesis of the male rat kidney effect (1). We selected Decalin as a prototype compound for investigation. Understanding the pathogenesis provides a data base for extrapolation to man in safety assessment and for extrapolation to other similar test substances that also appear to induce a similar species and sex-specific renal pathologic response in biologic teiting.
PATHOGENESIS OF DECALIN NEPHROTOXICITY
Through time course and dose-response studies with Decalin, the prototype volatile hydrocarbon, the induction and exacerbation of hyaline droplets in the cytoplasm of proximal convoluted tubular (PCT) cell cytoplasm is recognized as the primary response in the male rat ( Fig. 1) . Increased doses induce increased quantities of hyaline droplet accumulation with resultant PCT cell necrosis. Granular casts lodge at the junction of the inner and outer band of the outer zone of the medulla as a secondary effect of exacerbated hyaline droplet accumulation (Fig. 2 ). Chronic glomerulonephrosis develops as a tertiary response in that a secondary effect of nephron obstruction by the granular cast contributes to its development. This Decalinassociated chronic glomerulonephrosis is light microscopically undifferentiable from the spontaneous age-associated glomeruloncphrosis of laboratory rats.
Hyaline droplets occur spontaneously and commonly in sexuaIly maturing male rats, that is, rats over 40 days of age. This occurrence can be noted prior to onset of spontaneous glomerulonephrosis. Hyaline droplets in young sexually mature male rats are known to represent phagolysosomes filled with protein reabsorbed from the glomerular filtrate in tubular lumena. Light microscopically visible evidence of this in the routinely processed 5 -p thick, hematoxylin and eosinstained normal kidney section is restricted to the male rat, in contrast to absence in other provides a useful tool when quantitative morphometry or automated image analysis is utilized in volatile hydrocarbon investigations (Fig. 3) Ultrastructurally, tubular epithelial cells from male rats acutely exposed to Decalin differ only quantitatively from control males. The quantitative difference is restricted to the size or volume of lysosomal proteinic reabsorption bodies or phagolysosomes corresponding to the hyaline droplet observed at the light microscopic level (3). Many of the. male rats (treated and controls) with hyaline droplet accumulations have crystalloid bodies within the phagolysosomes (Fig. 4) . Similar crystalloid changes are not observed ultrastructurally in female controls, nor in other common laboratory mammals, nor man. Hence, we can (as others have] characterize the hyaline droplet in the otherwise normal control rat kidney as evidence of an androgen-dependent inefficiency of protein reabsorption/catabolism. Thus, we know that the male rat PCT has a physiologic peculiarity not shared by man or other common laboratory animals recognized by light and electron microscopy.
Classically, in man and domestic animals, induced hyaline droplet formation is usually a response to increased glomerular permeability. This is manifested as albuminuria, with formation of hyaline droplets containing primarily albumin or its catabolic products. Our investigations have discounted this mechanism in young mature male rats with spontaneous hyaline droplet formation.
Biochemically we have demonstrated that the hyaline droplet accumulation in normal mature male rats consists of a,,-globulin. aZu-Globulin is the major normal male rat urinary protein. This protein is synthesized in the liver under the synergistic control of testosterone and endogenous corticosterone (2, 4) . This protein has a molecular weight about 18,000 to 20.000 and is filtered freely through the glomerulus, then reabsorbed by PCT in the normal male. This protein does not occur in immature normal male rats (2) nor in.female rats or in any other species of either sex. Using state-of-the-art protein biochemistry technology, we have demonstrated that the Decalin biochemical effect is manifested as an increase in cu,,-globulin in renal cortex epithelial cell lysosomes.
Unexpectedly in our studies, inhalation controls often were unaffected, whereas gavage controls were uniformly affected with spontaneous hyaline droplet formation. The synergistic influence of endogenous corticosterone could explain the heretofore inexplicable variation in hyaline droplet incidence in controls. Gavage studies were considered to be more stressful because of the handling associated with treatment. These rats were housed in metabolism cages and were har-nessed with fecal cups during the study, in contrast to the rats in inhalation studies. We have not yet demonstrated (a) whether the Decalin effect occurs at the hepatocyte level with increased production of a,,-globulin and hence, overloading of the tubular reabsorption systems; (b) whether Decalin or its metabolites form an undigestible complex with a,,-globulin; [c) whether Decalin or its metabolites somehow inhibit normal male rat PCT lysosomal catabolic activity; and/or (d) whether the mechanism of action is a combination of the three previously mentioned. Regardless of which of the above apply, we can state that the acute and subchronic kidney effect of Decalin as a volatile hydrocarbon prototype is unique to the male rat since (1) the male rat is uniquely predisposed (through anatomic and physiologic peculiarities) to spontaneous hyaline droplet formation, and 2) biochemically the primary change in the kidney involves, and is limited to, alteration of the quantity of a specific protein that is unique to the male rat.
Indeed Decalin has been demonstrated to have no renal histomorphologic effect in female rats or other species of either sex, including mice, guinea pigs, and dogs.
As somc of you are aware, some volatile hydrocarbons have also been associated with renal tubular tumorigenicity in male rats, although in low incidence, for example, gasoline, RJ-5, and JP10. The operational concept of pathologists investigating this effect (Drs. R. Brunner, Craig, Trump, and W. Busey) states that the development of toxicity is prerequisite to the development of the tumorigenic response. If this is so then the tumorigenic response could also be considered a unique response in the rat. This concept is currently being tested by the American Petroleum Institute.
REFINING THE RISK ASSESSMENT
In this model, motivation for exploring the nephrotoxic response arose, in part, because of the critically important nature of the test substances, compounds that can't readily be discarded. The occurrence of an effect considered potentially serious with marginally acceptable safety factors of an important chemical class thus indicated need to understand the nature of the male rat alteration. Subsequently, following scrutiny of the literature and other relevant data questioning of the male rat kidney predictiveness was predicated on recognition of continuity between studies (a) of the same compound in different species with only male rat kidneys affected and female rats and other species consistently unaffected and (b) of different but related compounds with male rats constantly affected with a specific spectrum of renal cortical lesions. Of the classical means (Table 11) for further definition of the risk we chose mechanistic/pathogenesis studies as the most useful for developing an understanding of the male rat response in this specific situation.
